NO834087L - Fremgangsmaate for fremstilling av cytotoksiske midler - Google Patents
Fremgangsmaate for fremstilling av cytotoksiske midlerInfo
- Publication number
- NO834087L NO834087L NO834087A NO834087A NO834087L NO 834087 L NO834087 L NO 834087L NO 834087 A NO834087 A NO 834087A NO 834087 A NO834087 A NO 834087A NO 834087 L NO834087 L NO 834087L
- Authority
- NO
- Norway
- Prior art keywords
- chloroquine
- immunotoxin
- cytotoxic
- immunotoxins
- cytotoxicity
- Prior art date
Links
- 229940127089 cytotoxic agent Drugs 0.000 title claims description 3
- 239000002254 cytotoxic agent Substances 0.000 title claims description 3
- 231100000599 cytotoxic agent Toxicity 0.000 title claims description 3
- 238000004519 manufacturing process Methods 0.000 title description 3
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229940051026 immunotoxin Drugs 0.000 claims abstract description 28
- 230000002637 immunotoxin Effects 0.000 claims abstract description 28
- 239000002596 immunotoxin Substances 0.000 claims abstract description 28
- 231100000608 immunotoxin Toxicity 0.000 claims abstract description 28
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims description 28
- 229960003677 chloroquine Drugs 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 230000001472 cytotoxic effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000003013 cytotoxicity Effects 0.000 description 10
- 231100000135 cytotoxicity Toxicity 0.000 description 10
- 108010039491 Ricin Proteins 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 231100000433 cytotoxic Toxicity 0.000 description 8
- 238000010348 incorporation Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000003550 marker Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 4
- 230000001133 acceleration Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- -1 ammonium ions Chemical class 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8204047A FR2522968B1 (fr) | 1982-03-10 | 1982-03-10 | Medicament cytotoxique forme de l'association d'a u moins une immunotoxine et de la chloroquine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO834087L true NO834087L (no) | 1983-11-09 |
Family
ID=9271836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO834087A NO834087L (no) | 1982-03-10 | 1983-11-09 | Fremgangsmaate for fremstilling av cytotoksiske midler |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4582703A (de) |
| EP (1) | EP0088694B1 (de) |
| JP (1) | JPS59500370A (de) |
| AT (1) | ATE20519T1 (de) |
| DE (1) | DE3364240D1 (de) |
| FR (1) | FR2522968B1 (de) |
| NO (1) | NO834087L (de) |
| WO (1) | WO1983003055A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2516794B1 (fr) * | 1981-11-20 | 1985-10-25 | Sanofi Sa | Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique |
| CA1314245C (en) * | 1984-05-23 | 1993-03-09 | Franz Jansen | Process for the preparation of conjugates in which a monovalent carboxylic ionophore is associated by means of a covalent bond with a macromolecule, which are useful as immunotoxin potentiators |
| FR2573656B1 (fr) * | 1984-11-29 | 1987-02-27 | Sanofi Sa | Medicament comportant en tant qu'association au moins une immunotoxine et au moins un polymere contenant du mannose |
| CA1335227C (en) * | 1987-06-22 | 1995-04-11 | Wylie W. Vale, Jr. | Crf analog conjugates |
| WO1990010457A1 (en) * | 1989-03-14 | 1990-09-20 | New York University | Method of treating hiv infections using immunotoxins |
| US5112607A (en) * | 1991-06-05 | 1992-05-12 | The United States Of America As Represented By The Secretary Of The Army | Potentiation of immunotoxin action by Brefeldin A |
| GB0507672D0 (en) * | 2005-04-15 | 2005-05-25 | Barnaba Vincenzo | Adjuvant |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2437213A1 (fr) * | 1978-09-28 | 1980-04-25 | Cm Ind | Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation |
| FR2466252A2 (fr) * | 1979-10-03 | 1981-04-10 | Clin Midy | Nouveaux produits ayant notamment des proprietes anticancereuses a base de chaine a de la ricine et d'une proteine |
-
1982
- 1982-03-10 FR FR8204047A patent/FR2522968B1/fr not_active Expired
-
1983
- 1983-03-07 AT AT83400459T patent/ATE20519T1/de not_active IP Right Cessation
- 1983-03-07 WO PCT/FR1983/000044 patent/WO1983003055A1/en unknown
- 1983-03-07 EP EP83400459A patent/EP0088694B1/de not_active Expired
- 1983-03-07 DE DE8383400459T patent/DE3364240D1/de not_active Expired
- 1983-03-07 JP JP58500899A patent/JPS59500370A/ja active Granted
- 1983-03-07 US US06/552,052 patent/US4582703A/en not_active Expired - Fee Related
- 1983-11-09 NO NO834087A patent/NO834087L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE3364240D1 (en) | 1986-07-31 |
| US4582703A (en) | 1986-04-15 |
| WO1983003055A1 (en) | 1983-09-15 |
| FR2522968B1 (fr) | 1986-03-28 |
| JPH0455172B2 (de) | 1992-09-02 |
| JPS59500370A (ja) | 1984-03-08 |
| EP0088694A1 (de) | 1983-09-14 |
| EP0088694B1 (de) | 1986-06-25 |
| FR2522968A1 (fr) | 1983-09-16 |
| ATE20519T1 (de) | 1986-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220105191A1 (en) | Bioorthogonal compositions | |
| Eisler | Chrysotherapy: a synoptic review | |
| Bialer | Comparative pharmacokinetics of the newer antiepileptic drugs | |
| Dilda et al. | Arsenical-based cancer drugs | |
| TWI375563B (en) | Methods and compositions for treating tumors and metastatic disease | |
| Aboud-Pirak et al. | Inhibition of human tumor growth in nude mice by a conjugate of doxorubicin with monoclonal antibodies to epidermal growth factor receptor. | |
| US20230110128A1 (en) | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor | |
| KR102015524B1 (ko) | 압타머-약물 콘쥬게이트 및 그 용도 | |
| JP2010526821A5 (de) | ||
| JP2014502280A (ja) | Ｃｄ３８を特異的に認識する抗体とボルテゾミブを含有する抗腫瘍性の組合せ | |
| WO1994016729A1 (en) | Targeted nitric oxide pathway or nitric oxide synthase modulation | |
| JP2020510039A5 (de) | ||
| Roffler et al. | Potentiation of radioimmunotherapy by inhibition of topoisomerase I | |
| KR900015724A (ko) | 메베버린 용량 형태 | |
| NO834087L (no) | Fremgangsmaate for fremstilling av cytotoksiske midler | |
| KR20080071182A (ko) | 9-옥소아크리딘-10-아세트산 및 1-알킬아미노-1-데옥시폴리올의 염, 이들을 포함하는 약학적 조성물 및 치료 방법 | |
| Akiyama et al. | Potentiation of cytotoxic activity of immunotoxins on cultured human cells | |
| Rubens | Antibodies as carriers of anticancer agents | |
| JP2018506533A5 (de) | ||
| Blakey et al. | Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug | |
| FitzGerald et al. | Antitumor activity of a thioether-linked immunotoxin: OVB3-PE | |
| JPH0455173B2 (de) | ||
| NO833641L (no) | Medikamenter som omfatter minst ett immunotoksin og minst en enverdig karboksylisk ionofor | |
| JPH02504267A (ja) | 肝遮断薬 | |
| Flavell et al. | Effectiveness of combinations of bispecific antibodies for delivering saporin to human acute T-cell lymphoblastic leukaemia cell lines via CD7 and CD38 as cellular target molecules |